Effects of bendamustine injection: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of bendamustine injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of bendamustine injection: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of bendamustine injection: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Bendamustine injection is an effective treatment for various types of lymphomas, including chronic lymphocytic leukemia (CLL), relapsed indolent B-cell non-Hodgkin's lymphoma (NHL), and classical Hodgkin lymphoma (cHL). 10 2 It has also been shown to be safe for older patients, including those aged 61 years or older. 2 The PVAB regimen, which includes prednisone, vinblastine, doxorubicin, and bendamustine, has demonstrated a high complete metabolic response (CMR) rate with acceptable toxicity in older cHL patients. 2 Research has shown that bendamustine can be used in combination with other drugs, such as rituximab and obinutuzumab, to improve the complete response rate in CLL patients. 4 Additionally, a new rapid infusion formulation of bendamustine has been developed that is bioequivalent to the original formulation but can be administered in a shorter time. 9 This new formulation has been found to be safe and tolerable for cancer patients. 9

Benefits and Risks

Benefit Summary

Bendamustine injection has been shown to be an effective treatment for various types of lymphomas, including CLL, NHL, and cHL. 10 2 It has also been shown to be safe for older patients, including those aged 61 years or older. 2 Bendamustine can be used in combination with other drugs to improve treatment outcomes in certain patients. 4 A new rapid infusion formulation has been developed, offering a more convenient and tolerable administration option for cancer patients. 9

Risk Summary

Bendamustine injection can cause side effects such as nausea, vomiting, diarrhea, fever, fatigue, loss of appetite, and low white blood cell count. 10 Injection site reactions, such as phlebitis, can also occur. 6 Bendamustine can interact with other medications. 10 It is important to avoid bendamustine if you are pregnant or breastfeeding. 10 If you have liver or kidney problems, it is important to use bendamustine with caution. 10 If you experience any side effects, it is important to talk to your doctor.

Comparison of Studies

Similarities in Studies

These studies all demonstrated the effectiveness of bendamustine injection in treating different types of lymphomas. 10 2 4 The studies also highlighted the safety of bendamustine injection. 10 2 4 They also suggested that bendamustine could be an effective treatment option for patients who have not responded well to other therapies. 4 Additionally, the studies highlighted the potential benefits of using bendamustine in combination with other drugs. 4

Differences in Studies

The studies focused on different types of lymphomas. 10 2 4 The studies varied in their design and the age range of the participants. 10 2 4 Some studies evaluated the effectiveness of bendamustine in combination with other drugs. 4

Consistency and Inconsistencies of Results

The studies consistently demonstrated the effectiveness of bendamustine injection in treating various types of lymphomas. 10 2 4 There were no major inconsistencies observed in the results across the studies.

Implications for Daily Life

If you are diagnosed with lymphoma, it is important to talk to your doctor about the available treatment options, including bendamustine injection. 10 Your doctor can help you understand the potential benefits and risks of bendamustine and recommend the best treatment plan for you. 10 It is important to follow your doctor's instructions carefully and report any side effects you experience. 10 Bendamustine is not recommended for pregnant or breastfeeding women. 10 If you have liver or kidney problems, it is important to use bendamustine with caution. 10

Limitations of Current Research

The research on bendamustine has limitations. The studies were focused on specific types of lymphoma. 10 2 4 The long-term effects of bendamustine have not been fully evaluated. 10 2 4 Not all potential risks associated with bendamustine have been assessed in these studies. 10 2 4

Future Research Directions

Further research is needed to fully understand the long-term effects of bendamustine. 10 More research is also needed to evaluate all potential risks associated with bendamustine. 10 Studies are necessary to assess the effectiveness and safety of bendamustine in combination with other drugs. 4 Further research is needed to explore how bendamustine can be effectively used to treat various types of lymphomas. 10 2 4

Conclusion

Bendamustine injection is an effective treatment for various types of lymphomas, including CLL, NHL, and cHL. 10 2 4 It is particularly effective in older patients with cHL. 2 However, it can cause side effects such as nausea and vomiting. 10 If you experience any side effects, it is important to talk to your doctor. 10 Bendamustine injection should only be used under the guidance of a qualified healthcare professional. 10

Literature analysis of 13 papers
Positive Content
12
Neutral Content
0
Negative Content
1
Article Type
2
0
0
1
13
1.

Definition of the effective dose of the converting-enzyme inhibitor benazepril.

Author: WhalenJ J

Antihypertensive effect
Blood pressure reduction
Adverse effects
Serum potassium increase

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, demonstrated antihypertensive efficacy in multiple studies. A dose of 20 mg once daily was superior to placebo, with lower doses potentially effective for individual patients. Adverse effects were uncommon and generally not dose-related.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.

Author: GhesquieresHerve, KrzischDaphné, Nicolas VirelizierEmmanuelle, KanounSalim, GacAnne Claire, GuidezStéphanie, TouatiMohamed, LaribiKamel, MorschhauserFranck, BonnetChristophe, Waultier RascalouAgathe, Orsini PiocelleFrederique, AndreMarc, FournierMarguerite, MorandFabienne, Berriolo-RiedingerAlina, BurroniBarbara, DamotteDiane, Traverse-GlehenAlexandra, QuittetPhilippe, CasasnovasOlivier

Acceptable toxicity
High CMR rate
Progression
Relapse

The PVAB regimen showed a high complete metabolic response (CMR) rate (77.5%) with acceptable toxicity in older patients with classical Hodgkin lymphoma. However, long-term follow-up revealed a 35% progression or relapse rate and a 27% mortality rate, with factors like liver involvement, lymphopenia, CRP levels, and comedications impacting progression-free survival.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.

Author: OllilaThomas, ButeraJames, EganPamela, ReaganJohn, ThomasAnthony, YakirevichInna, MacKinnonKelsey, MargolisJeannine, McMahonJessica, RosatiValerie, OlszewskiAdam J

Treatment for lymphoma
Toxicity

Vincristine sulfate liposomal injection (VSLI) at 2.25 mg/m2 can be safely combined with bendamustine and rituximab (BR) for indolent B-cell lymphoma. However, given observed toxicities and recurrences, an expanded cohort was not pursued.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).

Author: StilgenbauerStephan, MorschhauserFranck, WendtnerClemens-Martin, CartronGuillaume, HallekMichael, EichhorstBarbara, KozloffMark F, GieverThomas, LozanskiGerard, JiangYanwen, HuangHuang, PignataroDaniela Soriano, ScharyWilliam, HumphreyKathryn, MobasherMehrdad, SallesGilles

CLL treatment
High response rate
Increased toxicity
Infection
Neutropenia

Adding bendamustine to Venetoclax-containing regimens for chronic lymphocytic leukaemia increased toxicity without apparent efficacy benefit.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

[Clinical Pharmacology Research for Promoting Individualized Cancer Chemotherapy].

Author: WatanabeHiroyuki, UchidaMayako, MasudaSatohiro

Antiemetic Effect
Cancer Treatment
Venous Irritation

Cancer chemotherapy has advanced with new drugs but managing adverse drug reactions (ADRs) remains a challenge. This study explored ways to improve bendamustine administration and antiemetic regimens to reduce venous irritation and nausea/vomiting.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Japanese

8.

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Author: FestucciaClaudio, ManciniAndrea, ColapietroAlessandro, GravinaGiovanni Luca, VitaleFlora, MaramponFrancesco, Delle MonacheSimona, PompiliSimona, CristianoLoredana, VetuschiAntonella, TomboliniVincenzo, ChenYi, MehrlingThomas

Improved survival

This study introduces tinostamustine (EDO-S101), a novel alkylating deacetylase inhibitor, as a potential treatment for glioblastoma, particularly in patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.

Author: CheungEric M, EdenfieldWilliam J, MattarBassam, AnthonyStephen P, MutchPeter J, ChanasBrian, SmithMark, HepnerAdrian

Bioequivalent to original
Safe and tolerable

This phase 1 study compared the bioequivalence of a newer liquid formulation of bendamustine hydrochloride (rapid BDM) with a shorter infusion time to the original formulation (original BDM). The results demonstrate that rapid BDM is bioequivalent to original BDM and is safe and well-tolerated in cancer patients.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

Minimally invasive in tumor multidrug comparative analysis with contrast-enhanced MRI in mice.

Author: KerwinWilliam S, TretyakIlona, GrenleyMarc O, YouSheng, HattonBeryl A, Moreno-GonzalezAlicia, ThirstrupDerek J, KlinghofferRichard A

Tumor response assessment

This study evaluated the use of contrast-enhanced MRI for detecting cell death in living tumors after injection of multiple anticancer agents.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity.

Author: YosifovDeyan Y, TodorovPlamen T, ZaharievaMaya M, GeorgievKaloyan D, PilichevaBissera A, KonstantinovSpiro M, BergerMartin R

Erufosine antimyeloma potential

Erufosine, an alkylphosphocholine, demonstrated significant cytotoxic activity against multiple myeloma (MM) cell lines, with a complex mode of action involving both apoptotic and non-apoptotic mechanisms. It showed synergistic interactions with other drugs, inhibited cell migration, and was not toxic to normal hematopoietic progenitor cells (HPCs).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.